Matrixyl

What is Matrixyl?

animal model

Matrixyl is a short protein fragment with a fatty tail attached, sold to cosmetic makers for creams and serums aimed at wrinkles. The fragment is five amino acids long, written KTTKS, and the tail is palmitic acid, a common fat found in palm oil and in the human body. A 2013 laboratory study of the molecule notes that it is used in anti-wrinkle skin care under the trade name Matrixyl.2

The fragment was not invented from nothing. A 2007 paper identifies KTTKS as a small piece of the precursor molecule the body uses to assemble type I collagen7, the principal structural protein of skin. That origin is the whole selling point: a piece of collagen that is meant to prompt the making of more collagen.

The fatty tail is there to help it into the skin. A 2019 formulation study explains that unmodified KTTKS barely crosses the skin because it dissolves so readily in water, which is why the palmitoylated version, Pal-KTTKS, is the one used in cosmetic products.8 Whether the tail does enough is a separate question, and the answer further down is only partly reassuring.

Is Matrixyl the same as palmitoyl pentapeptide-4?

human pilot / early trial

Yes, in the sense the ingredient label intends, though the naming is untidy. Palmitoyl pentapeptide-4 is the ingredient-list name for Pal-KTTKS, and most papers treat the two names as the same thing. A 2022 study spells out the relationship: pentapeptide-4 is the sequence KTTKS, and its palmitoyl derivative is the well-known cosmetic ingredient Matrixyl.9

Not every paper agrees on the number. A 2019 paper calls the identical molecule palmitoyl pentapeptide-310, a different designation for the same substance. A 2011 review went further, cautioning that KTTKS has become erroneously associated with the generic term pentapeptide3, which fits any chain of five amino acids rather than this one.

For a reader comparing labels, the safer guide is the sequence rather than the number. Pal-KTTKS, or the full chain of five amino acids written out by name, can only mean one thing. "Pentapeptide" on its own can mean many, and so can the trade name once Matrixyl 3000 enters the picture.

What is the difference between Matrixyl 3000 and Matrixyl synthe 6?

human RCT

The one study among these sources that identifies the contents of Matrixyl 3000 lists two peptides, and the original Matrixyl peptide is not one of them. A 2026 skin permeation study lists palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR) as the peptides present in Matrixyl 3000.6 Both carry the same palmitoyl tail as Pal-KTTKS, which is where the family resemblance ends.

The same combination appears in other research without the brand name. A 2024 eye-cream trial lists palmityl tripeptide-1 and palmitoyl tetrapeptide-7 among its active ingredients11, alongside a fermented yeast and rice filtrate and a sugar derivative, so its results belong to that complete formulation rather than to the two peptides individually.

Matrixyl synthe'6 is a third commercial product, and none of the studies behind this page mentions it, so its composition and how it differs from the other two cannot be described from them. What this does tell a reader is that Matrixyl is a brand family rather than a single molecule. A result reported for Matrixyl concerns Pal-KTTKS; a result reported for Matrixyl 3000 concerns the GHK and GQPR combination, and is not the same evidence.

What does Matrixyl peptide do?

human RCT

In lab experiments, it prompts skin cells to make more of the proteins that give skin its structure. On human faces, it has been measured to reduce the look of fine lines in one well-controlled trial. Those are two different claims, and the distance between them is the most important thing to understand about this ingredient.

The 2005 trial paper states the design plainly: pal-KTTKS was built as a topical agent to stimulate collagen production and so provide an anti-wrinkle benefit.1 A 2011 review considered the cell evidence sound, describing a stimulatory effect on the extracellular matrix, the protein network that skin cells construct around themselves.3

The step between the culture dish and the face is the one rarely measured. Wrinkle trials evaluate the surface of the skin, whereas collagen studies count protein made by cells in a dish. The same review identified relatively few clinical studies of these materials3, and among the human trials covered here, none took biopsies to measure collagen in the women whose lines improved. So "boosts collagen" describes the cell research and "reduces fine lines" describes the trial; the connection between them is assumed rather than demonstrated. What each study measured, outcome by outcome, is laid out on the Matrixyl benefits page.

Has Matrixyl been tested in people?

human RCT

Yes, in a handful of small, relatively short trials, nearly all of them in women. Two tested the peptide by itself; the others tested it as one component of a combination.

The first of the two: a 2005 trial gave 93 white women aged 35 to 55 the peptide cream on one side of the face and the identical moisturiser without it on the other side, for 12 weeks, with neither participants nor assessors knowing which side was which1. A split-face design is particularly strong for this question, because every woman serves as her own comparison. The second, published in 2023, assigned 21 Indonesian women to one of three creams applied around the eyes for eight weeks.

Three further trials tested combinations. Two 2009 split-face studies, enrolling 42 and 35 women aged 30 to 70, evaluated four products that each combined niacinamide, the peptides Pal-KT and Pal-KTTKS, and carnosine.12 A 2004 trial randomly assigned 20 breast cancer patients to a Matrixyl-containing cream or a conventional lotion during radiotherapy.13

Altogether, approximately 210 people participated in randomised trials of a cream containing the peptide, none of them for longer than 12 weeks. None of the trial abstracts behind this page identifies who funded the research or manufactured the test creams, so the question of who conducted them cannot be settled from those summaries. It is a genuine human record, and a short one.

What is Matrixyl serum used for?

human case report

For the appearance of ageing skin, and principally for fine lines and wrinkles, which is what every trial behind this page set out to measure. A 2012 review of how these ingredients were chosen lists the aims as a better look for aged skin, including fine lines, wrinkles and age spots.14 It names Pal-KTTKS alongside niacinamide, hexamidine, retinyl propionate and sodium dehydroacetate14, all picked out by testing which genes they switch on in skin cells grown in the lab.

In practice a serum is rarely Matrixyl alone. A 2026 case report describes a typical modern formula: a serum combining hyaluronic acid, niacinamide and Matrixyl.15 That is the usual pattern, and it changes what any result means. A measured effect belongs to the whole formula, and a serum that implies it does what Matrixyl did in its single-peptide trial is leaning on a test of a different mixture.

Is Matrixyl studied for anything besides wrinkles?

human RCT

Yes, and in the single human application the result was disappointing. Researchers have incorporated it into a cream intended to protect skin during breast radiotherapy, built it into experimental wound dressings, and attached its peptide to antibacterial molecules.

In the radiotherapy trial, the Matrixyl-containing cream showed no advantage over a lotion containing dexpanthenol13, a long-standing skin-care ingredient. That cream held two other actives, so the result describes the formula, but it is the only test among these sources of the peptide on human skin under real stress.

The wound and germ-killing work stays in cells and animals, and much of it uses altered molecules rather than Matrixyl itself. A 2019 study fused an antibacterial peptide to the Matrixyl sequence and found the hybrid retained Matrixyl's collagen-inducing behaviour in laboratory experiments16, the ultimate objective being a cream for infected wounds such as diabetic foot ulcers. A 2007 study found that KTTKS, without the palmitoyl tail, induced type I collagen in rat Achilles tendon cells.7 Those findings show the fragment acts on more than one kind of cell, which is not the same as helping a person with a wound of their own. The animal wound results are set out on the Matrixyl benefits page.

Does Matrixyl actually get into the skin?

animal model

Some of it does, but comparatively little reaches the depth where collagen is manufactured. The outer layer of skin evolved specifically to exclude foreign molecules, and penetration through it is the weakest link in the argument for any anti-wrinkle peptide.

In hairless mouse skin, a 2014 study detected pal-KTTKS in every layer, with the highest concentration in the outermost layer and roughly one fourteenth of that amount in the dermis5, which is the layer that matters for collagen. The unmodified peptide, without its palmitoyl tail, was not detected in any of the skin layers.5 So the modification functions as intended, up to a point.

Three years earlier, a 2011 review had highlighted a surprising absence of skin penetration data for these peptides.3 The 2014 measurements partially address that deficiency, but they come from mouse skin, which is not human facial skin, so they describe what is possible rather than what happens on a face. How researchers are attempting to solve the delivery problem, from microneedles to lipid carriers, is discussed on the Matrixyl benefits page.

How is Matrixyl thought to work?

animal model

The working theory is called the matrikine idea. When collagen is broken down, some of the small pieces are thought to act as messages telling skin cells that repair is needed. A 2011 paper summarises the concept in one sentence, identifying KTTKS as the kind of collagen fragment that in turn augments production of the skin's structural matrix.17 A Matrixyl cream, on this account, sends the message without any damage having happened.

There is a second, stranger strand. In water, Pal-KTTKS spontaneously organises itself into flat tapes and extended fibrous structures18, and a 2013 cell study interpreted its own results as evidence that this self-assembly and the stimulation of collagen production are interrelated2, because collagen production increased near the concentration at which those structures begin forming. If that interpretation is correct, the physical behaviour of the molecule in a cream may matter as much as its sequence.

Both are explanations built from cell and test-tube work. Neither has been examined in living human skin among the studies behind this page, and the detailed cell findings are presented on the Matrixyl benefits page.

Is Matrixyl safe to put on skin?

human RCT

The human record contains few documented harms, and it is too small and too brief to support much more than that. The clearest signal comes from the radiotherapy trial, where every adverse event turned up among the patients using the Matrixyl cream, including one suspected allergic reaction13, though that cream held two other actives as well. The longest trial ran for 12 weeks, and none of these sources follows anyone for a year.

That combination, occasional reports from short trials involving a few hundred participants, describes how little has been investigated rather than a clean bill of health. What is documented, reaction by reaction, along with the eye-area studies, the sensitive-skin evidence and the cell toxicity work, is gathered on the Matrixyl safety page.

Is Matrixyl regulated or approved?

animal model

Matrixyl is sold as a cosmetic ingredient, not as a medicine, and it is not approved by the FDA as a medicine for any indication. A cream that contains it is therefore a cosmetic in the eyes of the law, whatever its label may hint at.

A 2009 lab paper describes palmitoyl peptides as anti-ageing agents widely used in cosmetics19, and the same team built a test to measure how much Pal-KTTKS a cream really holds. Its results showed that the rest of the formula changes how much of the peptide is free to act19, which means the amount on a label and the amount that can do anything are not always the same.

A 2026 paper from the cosmetic safety field notes that the industry is moving away from animal safety tests toward newer ways of judging risk, and argues that the case for each peptide's safety has to change with them.20 That is the frame these ingredients now sit in, and it is a very different frame from the trials a medicine must pass before it is approved.

How much Matrixyl is in the creams that were tested?

human RCT

Very little, by weight. The 93-woman trial used a moisturiser containing 3 ppm of pal-KTTKS1, meaning three parts per million, and it is the only concentration of the peptide itself stated in the human trial summaries behind this page. The other trials describe their formulations by ingredient rather than by quantity, which makes their concentrations impossible to compare.

These are study settings, not a strength to look for on a label, and a lab strength measures something else again. A percentage in a cream describes what is spread across the skin surface; a percentage in a culture dish describes what is bathing the cells directly. The two cannot be compared, because only a fraction of what sits on the skin ever reaches the living cells underneath.

The delivery vehicle matters as well. In cultured mouse fibroblasts, the same peptide enclosed in liposomes, microscopic spheres made of fat molecules, stimulated more collagen production than the free peptide did21, so an identical quantity accomplishes different amounts of work depending on what carries it into the tissue.

What is Matrixyl commonly combined with?

human RCT

Almost always with something. Apart from the two single-peptide trials, every human formula behind this page mixed Pal-KTTKS with other actives, and niacinamide, a form of vitamin B3, turns up most often. The 2009 eye-area studies also tested a wrinkle treatment containing retinyl propionate12, a milder relative of retinol, alongside niacinamide and a second palmitoyl peptide.

That habit of mixing is why so few results can be pinned on Matrixyl by itself. How it compares with retinol, Argireline, copper peptides and vitamin C, and what is known when they are used together, is the subject of the Matrixyl comparison page; the muscle-relaxing peptides it is most often set against have their own pages at the Argireline overview and the SNAP-8 overview. The wider field of skin peptides, from collagen drinks to injected blends, is surveyed on the peptides-for-skin overview, and the peptide that carries copper has its own page at the Copper Peptides overview.